Access in all areas? A round up of developments in market access and HTA: part 5

Abstract

In this latest update, we explore the recent announcement by Canada’s Drug Agency (CDA-AMC, formerly CADTH) on their pilot to include the societal perspective in the evaluation of certain new medicines; a recent Office of Health Economics (OHE) report on the evaluation of HTA agency methods over time; and publications examining the impact of Project Orbis on patient access to oncology treatments.

Keywords

• canada’s drug agency
• health technology assessment
• market access
• office of health economics
• oncology
• patient access
• project orbis
• societal perspective